Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4088293

N#Cc1cccc(-c2cnn(-c3ccnc4[nH]ccc34)c2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.47
PRKCI P41743 2/20 0.45
GRM4 Q14833 1/20 0.42
SGK1 O00141 1/20 0.42
NEK1 Q96PY6 1/20 0.41
SYK P43405 2/20 0.39
JAK1 P23458 3/20 0.37
BRD4 O60885 1/20 0.37
SLC22A12 Q96S37 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
JAK2 O60674 3/20 0.37
PLCG1 P19174 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
PRKDC P78527 1/20 0.36
ATR Q13535 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL98775 0.91 GRM5 (0.56) GRM5PRKCIGRM4NEK1BRD4
Trifluoroacetic Acid SCHEMBL4093375 0.89 PRKCI (0.45) GRM5PRKCIGRM4NEK1JAK1
Trifluoroacetic Acid SCHEMBL4086835 0.89 PRKCI (0.48) PRKCIGRM4JAK1JAK2
Trifluoroacetic Acid SCHEMBL4086493 0.87 PRKCI (0.48) PRKCIGRM4SYKJAK1EGLN1
Trifluoroacetic Acid SCHEMBL4082559 0.87 PRKCI (0.43) PRKCIGRM4JAK1JAK2MEN1
Trifluoroacetic Acid SCHEMBL4082067 0.87 PRKCI (0.54) PRKCIGRM4JAK1JAK2
Trifluoroacetic Acid SCHEMBL4099689 0.86 PRKCI (0.47) PRKCIGRM4SYKJAK1JAK2
Trifluoroacetic Acid SCHEMBL4082497 0.85 GRM5 (0.48) GRM5PRKCISGK1NEK1SYK
Trifluoroacetic Acid SCHEMBL4097538 0.84 PRKCI (0.42) PRKCIGRM4SGK1NEK1JAK1
Trifluoroacetic Acid SCHEMBL4092161 0.84 JAK3 (0.43) PRKCIGRM4JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130137681-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2013-05-30 US disclosed
US-8415362-B2 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2013-04-09 US disclosed
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137681-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 GRM5 2793/4885PRKCI 304/4885GRM4 2958/4885
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 GRM5 2793/4885PRKCI 304/4885GRM4 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.